{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134284","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.704962+00:00","generated_at":"2026-06-02T09:45:54.371145+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX reports positive Phase 1a data for CX-904: no CRS, 33% response rate in pancreatic cancer","bullets":["CX-904 demonstrated favorable safety: no CRS of any grade in step-dosing; no Grade >1 CRS overall.","In 6 efficacy-evaluable pancreatic cancer patients, 2 confirmed partial responses (33%) and all 6 had disease control.","One patient achieved 83% tumor reduction at 6 mg; another 51% at 5 mg; both remained on treatment.","Preliminary PK/PD data support PROBODY T-cell engager mechanism: maintained masking and CD8+ T-cell margination.","Dose escalation continues; Phase 1b expansion in EGFR-positive tumors planned with partner Amgen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134284","json":"https://secwatch.observer/filing/0001193125-24-134284.json","markdown":"https://secwatch.observer/filing/0001193125-24-134284.md","text":"https://secwatch.observer/filing/0001193125-24-134284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524134284/0001193125-24-134284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524134284/d835346d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:45:54.371145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}